Vol.53 No.S-1 July 2005

In vitro activity of doripenem against gram-positive and gram-negative bcteria isolates

Kyoko Kuwahara-Arai and Keiichi Hiramatsu

Department of Bacteriology, School of Medicine, Juntendo University,
2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan

Abstract

The 90% minimum inhibitory concentrations (MIC₉₀) of the new 1-methylcarbapenem (DRPM) (Shionogi & Co., Ltd., Osaka) against clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), Staphylococcus epidermidis, Staphylococcus haemolyticus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Moraxella catarrhalis, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Morganella morganii, Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa were 0.1, 50, 25, 25, 0.2, ≤0.006, 6.25, >100, 0.025, 1.56, 0.1, 0.2, 6.25, 0.39, 1.56, 6.25, and 12.5 μg/mL, DRPM showed well-balanced activity against both gram-positive and gram-negative bacteria.
The PBPs binding inhibitory pattern of DRPM against MSSA and MRSA was almost the same as that of imipenem. Below 4 μg/mL concentrations, IPM manifested antibiotic activity against S. aureus, stronger than that of DRPM.
DRPM exbited higher binding affinity than imipenem to PBPs 3α, β of P. aeruginosa.

Key word

doripenem, carbapenem, antibacterial activity, PBP, population analysis

Received

January 11, 2005

Accepted

March 16, 2005

Jpn. J. Chemother. 53 (S-1): 17-23, 2005